Vandetanib and Lenvatinib for the Treatment of Thyroid Cancers
Journal of Advances in Medicine and Medical Research · pp. 1–5 · Published 2 Jan 2019
10.9734/JAMMR/2018/46474Abstract
Several drugs with Rearranged during Transfection (RET) kinase-inhibitory activity were recently introduced for thyroid cancer patients. RET gene aberrations were found in differentiated thyroid cancers and medullary thyroid cancers, subsets of thyroid cancers. Rearrangement of RET gene was found in differentiated thyroid cancers and point mutations were observed in medullary thyroid cancers, and both types of RET gene change result in the ligand-independent activation of RET kinase activity. Given the relationship of RET activity and thyroid cancers, RET inhibitors were developed as anti-tumor agents for thyroid cancers. Vandetanib, sorafenib, cabozantinib, and lenvatinib was approved drugs for thyroid cancer patients, and discovery and development processes of vandetanib and lenvatinib were discussed in this review.
Cited by 1
Smita Kumari, Sudhanshu Sharma, Dia Advani · Environmental Science and Pollution Research · 2021
Related research
- Breast Cancer in Thyroid Cancer Patients, can One lead to Another? — shares topic coverage
- Periodic Catatonia after Thyroid Cancer — shares topic coverage
- Biochemical Study of Gender Effect on Thyroid Cancer in the Egyptian Population — shares topic coverage
- SETTLE Tumor in Pregnant Women: A Diagnostic Dilemma — shares topic coverage
- What is the Impact of Serum Molecular Markers on the Diagnosis of Thyroid Cancers? A Comparison of Serum Molecular Markers with Invasive Biopsy Methods — shares topic coverage
Article metrics
Real usage data collected on this platform.
4
Page views
0
PDF downloads
0
Outbound clicks
1
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.